- Home
- URGN vs FFA Comparison
URGN vs FFA Comparison
Compare URGN & FFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- FFA
- Stock Information
- Founded
- URGN 2004
- FFA 2004
- Country
- URGN United States
- FFA United States
- Employees
- URGN N/A
- FFA N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- FFA Investment Managers
- Sector
- URGN Health Care
- FFA Finance
- Exchange
- URGN Nasdaq
- FFA Nasdaq
- Market Cap
- URGN 465.9M
- FFA 411.2M
- IPO Year
- URGN 2017
- FFA N/A
- Fundamental
- Price
- URGN $10.27
- FFA $20.85
- Analyst Decision
- URGN Strong Buy
- FFA
- Analyst Count
- URGN 5
- FFA 0
- Target Price
- URGN $44.50
- FFA N/A
- AVG Volume (30 Days)
- URGN 487.3K
- FFA 26.1K
- Earning Date
- URGN 03-13-2025
- FFA 01-01-0001
- Dividend Yield
- URGN N/A
- FFA 6.72%
- EPS Growth
- URGN N/A
- FFA N/A
- EPS
- URGN N/A
- FFA N/A
- Revenue
- URGN $89,363,000.00
- FFA N/A
- Revenue This Year
- URGN $13.39
- FFA N/A
- Revenue Next Year
- URGN $45.06
- FFA N/A
- P/E Ratio
- URGN N/A
- FFA N/A
- Revenue Growth
- URGN 15.64
- FFA N/A
- 52 Week Low
- URGN $9.78
- FFA $15.84
- 52 Week High
- URGN $20.70
- FFA $19.30
- Technical
- Relative Strength Index (RSI)
- URGN 39.53
- FFA 57.47
- Support Level
- URGN $10.12
- FFA $20.03
- Resistance Level
- URGN $10.96
- FFA $20.63
- Average True Range (ATR)
- URGN 0.57
- FFA 0.29
- MACD
- URGN -0.01
- FFA 0.03
- Stochastic Oscillator
- URGN 24.75
- FFA 92.13
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.